immune system
• survival of cultured B-1 B cells is increased 3-fold compared with wild-type cells
• survival of cultured B-1 B cells treated with death agonists (VP-16, doxorubicin, and staurosporin) is increased compared with similarly treated wild-type cells
|
• in the mesenteric lymph node
|
• in the mesenteric lymph node
|
• in the mesenteric lymph node
|
• in 40% of mice at 9 to 12 months
|
• older mice exhibit highly disorganized spleen architecture compared with wild-type mice
|
• in older mice with incidence increasing with age
|
• in older mice
|
• due to increased cell number that increases in incidence and severity over time
|
• the percentage of B220+ cells increase slightly while the percentage of CD8+ T cells is slightly decreased in the mesenteric lymph node compared to in wild-type mice
• enlarged blast-like B and T cells accumulate in the mesenteric lymph nodes unlike in wild-type mice
|
• due to increased cell number that increases in incidence and severity over time
|
neoplasm
• at 9 to 12 months, mice exhibit lymphoid tumors due to expansion of peritoneal B-1 B cell populations with infiltration into nonlymphoid tissues (lungs and kidneys)
|
hematopoietic system
• survival of cultured B-1 B cells is increased 3-fold compared with wild-type cells
• survival of cultured B-1 B cells treated with death agonists (VP-16, doxorubicin, and staurosporin) is increased compared with similarly treated wild-type cells
|
• in the mesenteric lymph node
|
• in the mesenteric lymph node
|
• in the mesenteric lymph node
|
• older mice exhibit highly disorganized spleen architecture compared with wild-type mice
|
• in older mice with incidence increasing with age
|
• in older mice
|
cellular
• survival of cultured B-1 B cells is increased 3-fold compared with wild-type cells
• survival of cultured B-1 B cells treated with death agonists (VP-16, doxorubicin, and staurosporin) is increased compared with similarly treated wild-type cells
|
growth/size/body
• in older mice with incidence increasing with age
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
chronic lymphocytic leukemia | DOID:1040 |
OMIM:109543 OMIM:151400 OMIM:609630 OMIM:612557 OMIM:612558 OMIM:612559 |
J:94628 |